HC Wainwright Issues Pessimistic Outlook for AARD Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – Research analysts at HC Wainwright decreased their Q2 2026 earnings per share estimates for shares of Aardvark Therapeutics in a report issued on Monday, July 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($1.05) for the quarter, down from their previous forecast of ($0.95). HC Wainwright currently has a “Neutral” rating and a $6.00 target price on the stock. The consensus estimate for Aardvark Therapeutics’ current full-year earnings is ($3.48) per share. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.80) EPS, Q1 2027 earnings at ($0.72) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.42) EPS and Q4 2027 earnings at ($0.35) EPS.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.99) earnings per share for the quarter.

Several other research firms have also issued reports on AARD. BTIG Research lowered shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Morgan Stanley reissued an “underweight” rating and set a $3.00 target price (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th. Weiss Ratings raised Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. Finally, B. Riley Financial reduced their price target on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $16.30.

Aardvark Therapeutics Stock Down 1.4%

NASDAQ AARD opened at $6.39 on Wednesday. The company has a market cap of $139.81 million, a PE ratio of -1.99 and a beta of 3.93. Aardvark Therapeutics has a 52 week low of $3.35 and a 52 week high of $17.94. The firm’s 50-day simple moving average is $4.81 and its two-hundred day simple moving average is $7.33.

Institutional Investors Weigh In On Aardvark Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC increased its stake in Aardvark Therapeutics by 5.9% in the 3rd quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock worth $18,073,000 after acquiring an additional 76,151 shares during the last quarter. Laurion Capital Management LP boosted its position in shares of Aardvark Therapeutics by 6.1% during the 3rd quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock valued at $13,951,000 after acquiring an additional 60,653 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Aardvark Therapeutics by 20.6% during the 3rd quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock valued at $7,386,000 after acquiring an additional 94,744 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Aardvark Therapeutics by 51.2% during the fourth quarter. Millennium Management LLC now owns 483,340 shares of the company’s stock worth $6,344,000 after purchasing an additional 163,717 shares in the last quarter. Finally, SymBiosis Capital Partners LLC purchased a new position in shares of Aardvark Therapeutics during the fourth quarter worth about $6,255,000.

Key Headlines Impacting Aardvark Therapeutics

Here are the key news stories impacting Aardvark Therapeutics this week:

• Neutral Sentiment: HC Wainwright reiterated a Neutral rating on Aardvark Therapeutics and maintained a $6.00 price target, signaling a cautious outlook rather than a clear bullish catalyst.
• Neutral Sentiment: The firm updated earnings estimates across several future quarters, showing continued expected losses but only modest forecast changes overall. This suggests analysts still see a challenging path to profitability, though it is not a major new shock for the stock.
• Negative Sentiment: Coverage focusing on the FDA hold on Aardvark’s PWS asset is likely reinforcing investor concerns about development delays, regulatory risk, and potential pressure on the company’s lead program.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.